AbbVie Inc. $ABBV Stock: Middleton & Co. Inc. MA Cuts Stake

Middleton & Co. Inc. MA lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 3.5% during the third quarter, Holdings Channel.com reports. The firm owned 72,606 shares of the company’s stock after selling 2,607 shares during the period. AbbVie accounts for about 2.0% of Middleton & Co. Inc. MA’s portfolio, making the stock its 12th largest position. Middleton & Co. Inc. MA’s holdings in AbbVie were worth $18,993,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Corient Private Wealth LP bought a new position in shares of AbbVie in the second quarter valued at about $559,736,000. Legal & General Group Plc acquired a new position in AbbVie during the 2nd quarter worth about $2,905,952,000. Jupiter Topco LLC acquired a new position in AbbVie during the 2nd quarter worth about $1,560,354,000. Diamant Asset Management Inc. lifted its position in AbbVie by 21,649.0% during the 1st quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock worth $798,456,000 after buying an additional 3,654,351 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in AbbVie during the 2nd quarter worth about $817,473,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

AbbVie Stock Up 0.0%

ABBV stock opened at $285.66 on Monday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $291.40. The company has a market cap of $504.70 billion, a P/E ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24. The business has a fifty day moving average of $266.33 and a 200-day moving average of $242.01.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts anticipate that AbbVie Inc. will post 13.93 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ABBV. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Wells Fargo & Company boosted their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Leerink Partners upped their target price on shares of AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Citigroup increased their price target on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Finally, Rothschild & Co Redburn raised their price target on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $279.86.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.